Glaxosmithkline Pharmaceuticals Ltd vs Pharmaids Pharmaceuticals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 03, 2026

Key Highlights

The Latest Trading Price of Glaxosmithkline Pharmaceuticals Ltd is ₹ 2335 as of 30 Apr 15:30 . The P/E Ratio of Glaxosmithkline Pharmaceuticals Ltd changed from 68.1 on March 2021 to 52.5 on March 2025 . This represents a CAGR of -5.07% over 5 yearsThe P/E Ratio of Pharmaids Pharmaceuticals Ltd changed from 89.4 on March 2022 to 0 on March 2025 . This represents a CAGR of -100.00% over 4 years The Market Cap of Glaxosmithkline Pharmaceuticals Ltd changed from ₹ 24401 crore on March 2021 to ₹ 48743 crore on March 2025 . This represents a CAGR of 14.84% over 5 yearsThe Market Cap of Pharmaids Pharmaceuticals Ltd changed from ₹ 12.9 crore on March 2022 to ₹ 242.18 crore on March 2025 . This represents a CAGR of 108.16% over 4 years The revenue of Glaxosmithkline Pharmaceuticals Ltd for the Dec '25 is ₹ 1091 crore as compare to the Sep '25 revenue of ₹ 1016 crore. This represent the growth of 7.4% The revenue of Pharmaids Pharmaceuticals Ltd for the Dec '25 is ₹ 5.51 crore as compare to the Sep '25 revenue of ₹ 11.63 crore. This represent the decline of -52.62% The ebitda of Glaxosmithkline Pharmaceuticals Ltd for the Dec '25 is ₹ 421.44 crore as compare to the Sep '25 ebitda of ₹ 371.94 crore. This represent the growth of 13.31% The ebitda of Pharmaids Pharmaceuticals Ltd for the Dec '25 is ₹ -2.83 crore as compare to the Sep '25 ebitda of ₹ -2.3 crore. This represent the growth of 23.04% The net profit of Glaxosmithkline Pharmaceuticals Ltd changed from ₹ 182.33 crore to ₹ 295.62 crore over 7 quarters. This represents a CAGR of 31.80% The net profit of Pharmaids Pharmaceuticals Ltd changed from ₹ -3.12 crore to ₹ -2.65 crore over 7 quarters. This represents a CAGR of -8.91% The Dividend Payout of Glaxosmithkline Pharmaceuticals Ltd changed from 142.13 % on March 2021 to 99.54 % on March 2025 . This represents a CAGR of -6.88% over 5 yearsThe Dividend Payout of Pharmaids Pharmaceuticals Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Glaxosmithkline Pharmaceuticals Ltd

GlaxoSmithKline Pharmaceuticals Limited was erstwhile incorporated as 'Glindia Limited' in November, 1924.
The Company' s name was changed to Glaxo (India) Limited' from Glindia Limited in year 1987 and further to 'GlaxoSmithKline Pharmaceuticals Limited' from Glaxo (India) Limited effective from October 22, 2001. GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of UK-based GSK Plc., a global biopharma company to unite science, technology and talent to get ahead of disease together.
The Company is headquartered in Mumbai and it has six branch offices, one manufacturing facility at Nashik in Maharashtra, 20 contract manufacturing organisations (CMOs) with regional and sales hubs across India.
The Company is engaged interalia, in the business of manufacturing, distributing and trading in pharmaceuticals.

About Pharmaids Pharmaceuticals Ltd

Pharmaids Pharmaceuticals Limited, incorporated in March, 1989 at Hyderabad, Telangana were suppliers of Quality Grade range of speciality chemicals, skin care, hospital care and generic products in the areas of Orthopedic, Neuro and Gastro etc.
The technical team used quality proven chemical compounds and standard processing methods maintaining proper hygiene standards.The Company is engaged in the business of contract research and manufacturing services. Emergent Bio Naturals Limited (EBNL) was amalgamated with the Company in 2019-20 and the Scheme of Amalgamation was effective on September 27, 2019.
Pursuant to the Scheme, 69,05,734 Equity Shares were allotted to Shareholders of Emergent Bio Naturals Limited on November 27, 2019. The Company acquired 25.5% stake as 1st tranche in Anugraha Chemicals, a Partnership Firm, registered under Karnataka Partnership Rules, 1954 on February 1, 2023.

FAQs for the comparison of Glaxosmithkline Pharmaceuticals Ltd and Pharmaids Pharmaceuticals Ltd

Which company has a larger market capitalization, Glaxosmithkline Pharmaceuticals Ltd or Pharmaids Pharmaceuticals Ltd?

Market cap of Glaxosmithkline Pharmaceuticals Ltd is 39,566 Cr while Market cap of Pharmaids Pharmaceuticals Ltd is 104 Cr

What are the key factors driving the stock performance of Glaxosmithkline Pharmaceuticals Ltd and Pharmaids Pharmaceuticals Ltd?

The stock performance of Glaxosmithkline Pharmaceuticals Ltd and Pharmaids Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Glaxosmithkline Pharmaceuticals Ltd and Pharmaids Pharmaceuticals Ltd?

As of May 3, 2026, the Glaxosmithkline Pharmaceuticals Ltd stock price is INR ₹2335.6. On the other hand, Pharmaids Pharmaceuticals Ltd stock price is INR ₹29.67.

How do dividend payouts of Glaxosmithkline Pharmaceuticals Ltd and Pharmaids Pharmaceuticals Ltd compare?

To compare the dividend payouts of Glaxosmithkline Pharmaceuticals Ltd and Pharmaids Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.